Start Over

Do not forget the kidney in graves' disease.

Authors :: Demir AN
Kara Z
Durcan E
Sulu C
Atar OA
Zulfaliyeva G
Karaca C
Ozkaya HM
Seyahi N
Konukoglu D
Gonen MS
Source :: International urology and nephrology [Int Urol Nephrol] 2023 Oct; Vol. 55 (10), pp. 2667-2673. Date of Electronic Publication: 2023 Apr 24.
Publication Year :: 2023
Abstract: Purpose: To investigate the prevalence of microalbuminuria and factors associated with microalbuminuria in Graves' Disease (GD).<br />Methods: This cross-sectional and single-center study included 99 patients with GD and 47 healthy controls (HC). Exclusion criteria such as active infection, uncontrolled diabetes, and chronic kidney disease were applied to the participants. The participants' clinical findings, comorbidities, drug use, laboratory tests, and thyroid antibody levels were recorded. Spot urine samples were collected and stored at - 80 ℃ to analyze the presence of microalbuminuria.<br />Results: The prevalence of microalbuminuria in patients with GD was 12.1%. The median microalbumin/creatinine ratio in spot urine (UACR) in patients with GD (9.49 mg/g [5.09-18.10]) was higher than in the HC group (7.99 mg/g [3.48-12.88], p = 0.033). UACR was correlated with thyroid-stimulating hormone receptor antibody (TRAb), thyroid-stimulating hormone (TSH), and free triiodothyronine (FT3) levels (p = 0.020, p = 0.006, p = 0.009 respectively). In the regression analysis, only the relationship between TRAb level and UACR remained (p = 0.040).<br />Conclusion: This study demonstrates an increased prevalence of microalbuminuria in patients with GD. There was a significant correlation between microalbuminuria and TRAb level in patients with GD. This relationship suggests that one of the underlying mechanisms of microalbuminuria seen in patients with GD may be autoimmunity.<br /> (© 2023. The Author(s), under exclusive licence to Springer Nature B.V.)